FDA approves nivolumab for adjuvant treatment of Stage IIB/C melanoma

[FDA]

On October 13, 2023, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for the adjuvant treatment of completely resected Stage IIB/C melanoma in patients 12 years and older.


Baca selengkapnya di : http://www.fda.gov...